Release date: 2024-08-29 17:32:04 Article From: Lucius Laos Recommended: 148
Stiripentol significantly reduces generalized seizures by enhancing GABAergic nerve conduction. Since its approval by the FDA, it has become an important drug to help patients control their seizures.
A detailed understanding of the indications for a drug can help patients and doctors choose drugs carefully.
Stiripentol is used to treat seizures associated with Dravet syndrome (DS) and is suitable for patients taking clobazam who are older than 6 months and weigh more than 7 kg.
There are currently no clinical data to support the use of stiripentol as a single treatment for Dravet syndrome.
Knowing the conditions for which a drug is suitable can help patients make better drug choices, and drug interactions should be understood before using a drug for treatment.
Patients should also be aware of the drug interactions before deciding on medication.
Potent CYP1A2, CYP3A4, or CYP2C19 inducers (e.g., rifampicin, phenytoin, phenobarbital, and carbamazepine) reduce the concentration of stiripentol. Concomitant use with these inducers should be avoided, or the dose should be adjusted.
Concomitant use of Stiripentol with other central nervous system depressants or alcohol may increase the risk of sedation and drowsiness.
Patients and physicians should be concerned about drug interactions and be more mindful when using drugs.
There are some important considerations to be aware of before using Stiripentol to help better manage the course of treatment.
Monitoring of the patient for drowsiness is recommended, especially when combined with clobazam. If lethargy occurs, consider reducing the initial dose of clobazam by 25%. If lethargy persists, a further reduction in the dose of clobazam and adjustment of other sedative anticonvulsants may be required. Inform patients that Stiripentol may affect mental alertness and avoid activities that require a high degree of concentration.
Stiripentol may cause decreased appetite and weight loss. Growth in pediatric patients should be monitored, and valproate doses adjusted if necessary to alleviate these adverse effects.
Patients should pay close attention to their drug reactions during treatment and carefully identify whether they are related to drug use.
[Warm tips] During the use of stitopentol, please conduct regular examinations and pay attention to possible adverse reactions. If you experience any discomfort or abnormal symptoms, please contact your doctor promptly.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: